

CLAIMS

We Claim:

1. A method for treating or preventing chronic kidney disease in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-*d*₄)methanone.
2. The method of claim 1 for treating chronic kidney disease in an individual in need thereof.
3. The method of claim 1 for preventing chronic kidney disease in an individual in need thereof.
4. A method for treating or preventing heart failure in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-*d*₄)methanone.
5. The method of claim 4 for treating heart failure in an individual in need thereof.
6. The method of claim 4 for preventing heart failure in an individual in need thereof.
7. A method for treating hypertension, coronary artery disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency, or a combination thereof, in an individual in need thereof, in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-*d*₄)methanone.
8. The method of any one of claims 1-7, wherein the therapeutically effective amount is from about 3 mg to about 1500 mg.
9. The method of any one of claims 1-8, wherein the therapeutically effective amount is from about 3 mg to about 600 mg.
10. The method of any one of claims 1-9, wherein the therapeutically effective amount is from about 5 mg to about 300 mg.
11. The method of any one of claims 1-10, wherein the therapeutically effective amount is from about 10 mg to about 200 mg.
12. The method of any one of claims 1-11, wherein the therapeutically effective amount is from about 10 mg to about 100 mg.
13. The method of any one of claims 1-12, wherein (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-*d*₄)methanone is administered orally.
14. The method of claim 13, wherein the therapeutically effective amount is taken with food.
15. The method of claim 13, wherein the therapeutically effective amount is taken without food.

16. The method of any one of claims 1-15, wherein the therapeutically effective amount is administered to the individual once per day.
17. The method of any one of claims 1-15, wherein the therapeutically effective amount is administered to the individual twice per day.
18. The method of any one of claims 1-17, further comprising administering at least one additional therapeutic agent.
19. The method of any one of claims 1-18, further comprising administering a xanthine oxidase inhibitor.
20. The method of claim 19, wherein the xanthine oxidase inhibitor is allopurinol, oxypurinol, febuxostat, topiroxostat, or inositol.
21. The method of any one of claims 1-20, further comprising administering an SGLT2 inhibitor.
22. The method of claim 21, wherein the SGLT2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, empagliflozin/linagliptin, empagliflozin/metformin, or dapagliflozin/metformin.
23. A pharmaceutical composition for use in the treatment or prevention of chronic kidney disease, wherein the pharmaceutical composition comprises a therapeutically effective amount of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-*d*₄)methanone, and at least one inactive ingredient selected from pharmaceutically acceptable carriers, diluents, and excipients.
24. The pharmaceutical composition of claim 23 for use in the treatment of chronic kidney disease in an individual in need thereof.
25. The pharmaceutical composition of claim 23 for use in the prevention of chronic kidney disease in an individual in need thereof.
26. A pharmaceutical composition for use in the treatment or prevention of heart failure, wherein the pharmaceutical composition comprises a therapeutically effective amount of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-*d*₄)methanone, and at least one inactive ingredient selected from pharmaceutically acceptable carriers, diluents, and excipients.
27. The pharmaceutical composition of claim 26 for use in the treatment of heart failure in an individual in need thereof.
28. The pharmaceutical composition of claim 26 for use in the prevention of heart failure in an individual in need thereof.
29. A pharmaceutical composition for use in the treatment of hypertension, coronary artery disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney stones, kidney failure,

diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency, or a combination thereof, wherein the pharmaceutical composition comprises a therapeutically effective amount of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-*d*₄)methanone, and at least one inactive ingredient selected from pharmaceutically acceptable carriers, diluents, and excipients.

30. The pharmaceutical composition of any one of claims 23-29, wherein the therapeutically effective amount is from about 3 mg to about 1500 mg.
31. The pharmaceutical composition of any one of claims 23-30, wherein the therapeutically effective amount is from about 3 mg to about 600 mg.
32. The pharmaceutical composition of any one of claims 23-31, wherein the therapeutically effective amount is from about 5 mg to about 300 mg.
33. The pharmaceutical composition of any one of claims 23-32, wherein the therapeutically effective amount is from about 10 mg to about 200 mg.
34. The pharmaceutical composition of any one of claims 23-33, wherein the therapeutically effective amount is from about 10 mg to about 100 mg.
35. The pharmaceutical composition of any one of claims 23-34, wherein the therapeutically effective amount is from about 25 mg to about 75 mg.
36. The pharmaceutical composition of any one of claims 23-35 formulated for oral, intravenous, intramuscular, or subcutaneous administration.
37. The pharmaceutical composition of any one of claims 23-36 formulated for oral administration.
38. The pharmaceutical composition of claim 37, wherein the therapeutically effective amount is taken with food.
39. The pharmaceutical composition of claim 37, wherein the therapeutically effective amount is taken without food.
40. The pharmaceutical composition of any one of claims 23-39, wherein the therapeutically effective amount is administered once per day.
41. The pharmaceutical composition of any one of claims 23-39, wherein the therapeutically effective amount is administered twice per day.
42. The pharmaceutical composition of any one of claims 23-41, further comprising at least one additional therapeutic agent.
43. The pharmaceutical composition of any one of claims 23-42, further comprising a xanthine oxidase inhibitor.

44. The pharmaceutical composition of claim 43, wherein the xanthine oxidase inhibitor is allopurinol, oxypurinol, febuxostat, topiroxostat, or inositol.
45. The pharmaceutical composition of any one of claims 23-44, further comprising administering an SGLT2 inhibitor.
46. The pharmaceutical composition of claim 45, wherein the SGLT2 inhibitor is canagliflozin, dapagliflozin, empagliflozin, empagliflozin/linagliptin, empagliflozin/metformin, or dapagliflozin/metformin.